Platelet Inhibition After Glycoprotein IIb/IIIa Inhibitor Therapy
نویسندگان
چکیده
منابع مشابه
Platelet inhibition after glycoprotein IIb/IIIa inhibitor therapy.
Inhibitor Therapy To the Editor: In their clinically sound GOLD (AU-Assessing Ultegra) study, Steinhubl et al1 reported striking results concerning the widely variable level of platelet function inhibition achieved with glycoprotein IIb/IIIa (GP IIb/IIIa) antagonists among patients undergoing percutaneous coronary intervention. They also documented the important clinical implications related to...
متن کاملMedical decision making with incomplete evidence--choosing a platelet glycoprotein IIbIIIa receptor inhibitor for percutaneous coronary interventions.
BACKGROUND Medical decision making must often be performed despite incomplete evidence. An example is the choice of a glycoprotein IIb/IIIa (GP2b3a) inhibitor, a class of potent antiplatelet medications, as adjunctive therapy during percutaneous coronary interventions (PCIs). GP2b3a inhibitor efficacy in reducing adverse outcomes has been well documented with multiple placebo-controlled randomi...
متن کاملAcquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies.
BACKGROUND A 75 year old patient presenting with mucocutaneous bleeding was diagnosed with acquired thrombasthenia. The diagnosis was based on lack of platelet aggregation with adenosine diphosphate (ADP), arachidonic acid and collagen, and normal aggregation induced by ristocetin. OBJECTIVE To study the mechanism of platelet function inhibition in a patient with acquired thrombasthenia. ME...
متن کاملPlatelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury.
There are many published articles on the effects of the antithrombolytic function of platelet glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa inhibitors) in myocardial infarction. However, few studies have explored the effects and optimal concentration of tirofibans in diminishing the extent of myocardial reperfusion injury (RI).Rats received 120 minutes of coronary ligation and 180 minutes of re...
متن کاملDeaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
BACKGROUND The glycoprotein (GP) IIb/IIIa inhibitors are potent antagonists of platelet aggregation that are approved to prevent thrombotic complications of percutaneous coronary intervention and for medical treatment of patients with acute coronary ischaemic syndromes. From safety data obtained from clinical trials, these agents appear to be associated with a definite but well tolerated increa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2001
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circ.104.25.e163